Symphogen attracts new usd 25 million investment

10-Jan-2006

Symphogen A/S announced the initial closing of a USD 25 million Series D financing at a premium to the last financing round. The financing will be used to carry out clinical trials of Symphogen's first product, anti-RhD for the treatment of idiopathic thrombocytopenic purpura (ITP) and engage in additional partnerships to leverage Symphogen's unique human polyclonal and monoclonal antibody discovery and production capabilities.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances